Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)

Scopus

Scopus profile and journal metrics

This journal is indexed in Scopus. Use these metrics for a quick publishing snapshot, then open the Scopus page for the authoritative profile.

Scopus
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Indexed in Scopus since 2022
CiteScore 1.0
Indexed since 2022
First decision 7 Days
Submission to acceptance 45 Days
Acceptance to publication 14 Days
Acceptance rate 8%

SCImago

SCImago Journal Rank preview

Use SCImago when you want a quick visual view of the journal ranking profile and external discoverability signals.

Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) SCImago Journal & Country Rank

DOAJ

Directory of Open Access Journals listing

The DOAJ record is useful for readers, librarians, and authors who want a direct open-access directory entry for the journal.

DOAJ
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Open directory record
Original full research article

Metrnl: A predictive marker of atherosclerosis among Rheumatoid Arthritis patients

Published
2025-02-22
Pages
11 - 16
Full text

Keywords

  • Rheumatoid arthritis
  • Carotid intima-media thickness
  • Atherosclerosis
  • Metrnl

Abstract

Metrnl is a novel secreted protein exerting pleiotropic effects on inflammation and metabolism. Metrnl is increased in rheumatoid arthritis patients, however, Metrnl deficiency causes endothelial dysfunction which in turn promotes atherosclerosis. This study aimed to analyze serum Metrnl in Rheumatoid Arthritis patients with and without atherosclerosis. A case-control study was conducted on 50 Rheumatoid patients compared with 50 sex and age-matched control group. Metrnl levels were measured in blood samples from patients and controls by Enzyme-linked immunosorbent assay (ELISA), and CIMT was measured using Doppler ultrasonography. Medical data were collected regarding the patients’ clinical manifestations, comorbidities, and treatments. The disease activity score-28 (DAS28) was used to evaluate the disease activity of RA. Metrnl, right, and left CIMT showed a significant increase in the RA group when compared to the control group. Metrnl level showed a significant negative correlation with CRP, cholesterol, right CIMT, and left CIMT. However, no significant correlation was found between Metrnl and other parameters. At a cut-off point, ≥1.0748 Metrnl level showed significant AUC with 65% specificity and 76% sensitivity. At cut-off point ≥ 0.55, right and left CIMT levels showed significant AUC with 82% specificity and 48% sensitivity for differentiation between cases and controls. Age, BMI, disease duration, Family history of premature atherosclerosis, CRP, ESR, TG, cholesterol level, LDL, HDL, and lower Metrnl were associated with increasing CIMT in rheumatoid patients in univariate analysis. However, in multivariate analysis, only age, ESR, TG, HDL, and Metrnl were associated with increasing CIMT in rheumatoid patients. In Conclusion: Metrnl increased in patients with RA while lower Metrnl levels were correlated with increased CIMT in cases. Age, BMI, disease duration, Family history of premature atherosclerosis, CRP, ESR, TG, cholesterol level, and LDL, were linked to an increase in CIMT in rheumatoid patients

Article history

Received
2024-09-04
Accepted
2025-02-21
Available online
2025-02-22
بحث أصيل كامل

Metrnl: A predictive marker of atherosclerosis among Rheumatoid Arthritis patients

Published
2025-02-22
الصفحات
11 - 16
البحث كاملا

الكلمات الإفتتاحية

  • Rheumatoid arthritis
  • Carotid intima-media thickness
  • Atherosclerosis
  • Metrnl

الملخص

Metrnl is a novel secreted protein exerting pleiotropic effects on inflammation and metabolism. Metrnl is increased in rheumatoid arthritis patients, however, Metrnl deficiency causes endothelial dysfunction which in turn promotes atherosclerosis. This study aimed to analyze serum Metrnl in Rheumatoid Arthritis patients with and without atherosclerosis. A case-control study was conducted on 50 Rheumatoid patients compared with 50 sex and age-matched control group. Metrnl levels were measured in blood samples from patients and controls by Enzyme-linked immunosorbent assay (ELISA), and CIMT was measured using Doppler ultrasonography. Medical data were collected regarding the patients’ clinical manifestations, comorbidities, and treatments. The disease activity score-28 (DAS28) was used to evaluate the disease activity of RA. Metrnl, right, and left CIMT showed a significant increase in the RA group when compared to the control group. Metrnl level showed a significant negative correlation with CRP, cholesterol, right CIMT, and left CIMT. However, no significant correlation was found between Metrnl and other parameters. At a cut-off point, ≥1.0748 Metrnl level showed significant AUC with 65% specificity and 76% sensitivity. At cut-off point ≥ 0.55, right and left CIMT levels showed significant AUC with 82% specificity and 48% sensitivity for differentiation between cases and controls. Age, BMI, disease duration, Family history of premature atherosclerosis, CRP, ESR, TG, cholesterol level, LDL, HDL, and lower Metrnl were associated with increasing CIMT in rheumatoid patients in univariate analysis. However, in multivariate analysis, only age, ESR, TG, HDL, and Metrnl were associated with increasing CIMT in rheumatoid patients. In Conclusion: Metrnl increased in patients with RA while lower Metrnl levels were correlated with increased CIMT in cases. Age, BMI, disease duration, Family history of premature atherosclerosis, CRP, ESR, TG, cholesterol level, and LDL, were linked to an increase in CIMT in rheumatoid patients

Article history

تاريخ التسليم
2024-09-04
تاريخ القبول
2025-02-21
Available online
2025-02-22